Estetra SRL
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Estetra SPRL (to 2021)
6
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Orodispersible Dosage Unit Containing an Estetrol Component (US 11,793,760) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Method for Preventing Pregnancy (US 11,896,602) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 2 fees due Oct 16 to 23, 2027 · next Oct 16
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,034,854 | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy In force · High confidence | In force | High confidence | |
| US 7,732,430 | Drug Delivery System Comprising a Tetrahydroxilated Estrogen for Use in Hormonal Contraception In force · High confidence | In force | High confidence | |
| US 8,236,785 | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method In force · From the USPTO record | In force | From the USPTO record | |
| US 8,367,647 | Treatment of meconium aspiration syndrome with estrogens In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,240 | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy In force · Medium confidence | In force | Medium confidence | |
| US 8,518,923 | Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,579,329 | Use of estetrol as emergency contraceptive In force · From the USPTO record | In force | From the USPTO record | |
| US 8,987,484 | Process for the Production of Estetrol In force · High confidence | In force | High confidence | |
| US 11,053,273 | Process for the production of estetrol intermediates In force · From the USPTO record | In force | From the USPTO record | |
| US 11,053,274 | Process for the production of estetrol intermediates In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 25: 1 patent in force now held by others · 3 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 1 abandoned